Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Why your gran’s not too old to be a millennial

And what does age really have to do with being a millennial? 

- PMLiVE

Pfizer rides out Sanofi and confirms $14bn Medivation takeover

Success of cancer specialist’s drug Xtandi followed by work on other cancer drugs

Sanofi reception

Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

FDA verdict on Novo Nordisk’s rival combo Xultophy due next month 

Meet Anthill at conferences in London

October, the month of multichannel pharma marketing in London. Meet us at DigiPharm and Multichannel Excellence Summit

Anthill Agency

- PMLiVE

Portola rejection hands advantage to Boehringer’s Pradaxa

FDA’s ruling on reversal agent for NOACs unexpected

- PMLiVE

J&J is to appeal Remicade patent ruling in US

As Pfizer is poised to bring biosimilar version to market

- PMLiVE

Strengthening market access deliverables by harnessing the patient journey

In today’s multi-stakeholder environment, pharma companies need to coordinate their stakeholder interactions between functions to ensure consistency of message and efficiency of cost.

Immuno-oncology; bringing patients closer to treatment

What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment?

Blue Latitude Health

- PMLiVE

Teva gets EU nod for severe asthma drug Cinqaero

Once-monthly dose able to improve asthma control

- PMLiVE

Case study: How strategic multichannel marketing defends a brand’s leadership positions

Traditionally, brands have used multichannel marketing (MCM) to build awareness across a broad range of targets. Building on that foundation, we worked with a large life science company whose established,...

- PMLiVE

ViiV takes two-drug cocktail for first-line HIV into phase III

New approach hopes to reduce drug exposure and improve adherence

- PMLiVE

J&J therapy for suicidal depressives ‘a breakthrough’, says FDA

Status granted to esketamine after phase II PeRSERVERe trial

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links